OPTN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 18:31):

Stats
Dzisiejszy wolumen	415 684
Średni wolumen	1.15M
Kapitalizacja rynkowa	116.03M
EPS	$0 ( 2024-03-07 )
Następna data zysków	( $-0.100 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.22
ATR14	$0.00600 (0.58%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Krick Anthony J	Sell	2 345	Common Stock
2024-03-15	Marino Michael F Iii	Buy	3 816	Common Stock
2024-03-18	Marino Michael F Iii	Sell	15 059	Common Stock
2024-03-15	Mahmoud Ramy A	Buy	6 114	Common Stock
2024-03-18	Mahmoud Ramy A	Sell	19 198	Common Stock

INSIDER POWER
-24.20
Last 98 transactions
Buy: 6 923 187 \| Sell: 11 541 596

OptiNose Inc Korelacja

10 Najbardziej pozytywne korelacje
FONR	0.899
EQIX	0.894
ULTA	0.872
GRPN	0.871
NUVL	0.868
CRSP	0.858
IPW	0.847
BIMI	0.846
KNSA	0.846
CTRN	0.84

10 Najbardziej negatywne korelacje
VMCAU	-0.869
LIVX	-0.854
LILA	-0.837
LILAK	-0.816
PCTTU	-0.809
GWAC	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OptiNose Inc Korelacja - Waluta/Towar

-0.52
( weak negative )

-0.21
( neutral )

0.00
( neutral )

-0.60
( weak negative )

-0.27
( neutral )

0.29
( neutral )

OptiNose Inc Finanse

Annual	2023
Przychody:	$70.99M
Zysk brutto:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2023
Przychody:	$70.99M
Zysk brutto:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2022
Przychody:	$76.28M
Zysk brutto:	$67.01M (87.86 %)
EPS:	$-0.890

FY	2021
Przychody:	$74.65M
Zysk brutto:	$65.50M (87.74 %)
EPS:	$-1.450

Financial Reports:

No articles found.

OptiNose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Aktualne aktualizacje dla OptiNose Inc [OPTN]

Upcoming Earnings Alert